Simon Rössler

@simonrossler.bsky.social

organic chemist attempting peptide drug discovery at Novo Nordisk | postdoc at MIT | PhD at ETH

My colleagues at Novo Nordisk have developed long-acting variants of PYY which, when combined with semaglutide, show promise in improving obesity and blood glucose regulation in preclinical models without muscle loss. Read more here: www.science.org/doi/10.1126/...

Variant screening of PYY3–36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity

A Y2 receptor–selective and long-acting PYY derivative improves weight loss and glucose metabolism in rodents in combination with a GLP-1 agonist.

science.org

MIT researchers in collaboration with Novo Nordisk report in Nature an alternative to injections for the delivery of biologic drugs. This needle-free method leverages an ingestible capsule inspired by squids that releases drugs directly into the digestive tract wall. www.nature.com/articles/s41...

Cephalopod-inspired jetting devices for gastrointestinal drug delivery - Nature

Tethered or ingestible delivery systems that deliver liquid microjets in axial and radial directions can be used to deliver macromolecules to different parts of the gastrointestinal tract with good bi...

nature.com

To tackle the challenge of proper glycaemic control for people on insulin therapy, my colleagues at Novo Nordisk have engineered a glucose-responsive insulin, which shows reduced activity at low glucose levels, thereby mitigating the risk of hypoglycemia. www.nature.com/articles/s41...

Glucose-sensitive insulin with attenuation of hypoglycaemia - Nature

NNC2215 is an insulin conjugate that can reversibly adjust its bioactivity in response to a diabetes-relevant glucose range in vivo.

nature.com